Ignite Creation Date:
2025-12-24 @ 11:43 PM
Ignite Modification Date:
2025-12-31 @ 5:40 AM
Study NCT ID:
NCT04428151
Status:
COMPLETED
Last Update Posted:
2025-12-04
First Post:
2020-06-09
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
7902-009
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |